1. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose. (4th November 2016) Authors: Krishna, Rajesh; East, Lilly; Larson, Patrick; Valiathan, Chandni; Deschamps, Kathleen; Luk, Julie Ann; Bethel‐Brown, Crystal; Manthos, Helen; Brejda, John; Gartner, Michael Journal: Biopharmaceutics & drug disposition Issue: Volume 37:Number 9(2016:Dec.) Page Start: 533 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir. (14th November 2016) Authors: Krishna, Rajesh; East, Lilly; Larson, Patrick; Siringhaus, Tara; Herpok, Lisa; Bethel‐Brown, Crystal; Manthos, Helen; Brejda, John; Gartner, Michael Journal: Biopharmaceutics & drug disposition Issue: Volume 37:Number 9(2016:Dec.) Page Start: 542 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. (27th September 2016) Authors: Krishna, Rajesh; East, Lilly; Larson, Patrick; Valiathan, Chandni; Butterfield, Kristin; Teng, Yang; Hernandez-Illas, Martha Journal: Journal of pharmacy and pharmacology Issue: Volume 68:Number 11(2016:Nov.) Page Start: 1359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of metal‐cation antacids on the pharmacokinetics of 1200 mg raltegravir. (27th September 2016) Authors: Krishna, Rajesh; East, Lilly; Larson, Patrick; Valiathan, Chandni; Butterfield, Kristin; Teng, Yang; Hernandez‐Illas, Martha Journal: Journal of pharmacy and pharmacology Issue: Volume 68:Number 11(2016:Nov.) Page Start: 1359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Issue 11 (November 2017) Authors: Cahn, Pedro; Kaplan, Richard; Sax, Paul E; Squires, Kathleen; Molina, Jean-Michel; Avihingsanon, Anchalee; Ratanasuwan, Winai; Rojas, Evelyn; Rassool, Mohammed; Bloch, Mark; Vandekerckhove, Linos; Ruane, Peter; Yazdanpanah, Yazdan; Katlama, Christine; Xu, Xia; Rodgers, Anthony; East, Lilly; Wenni... Journal: Lancet Issue: Volume 4:Issue 11(2017) Page Start: e486 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial. Issue 3 (29th June 2021) Authors: Wagner, Kathryn R.; Kuntz, Nancy L.; Koenig, Erica; East, Lilly; Upadhyay, Sameer; Han, Baoguang; Shieh, Perry B. Journal: Muscle & nerve Issue: Volume 64:Issue 3(2021) Page Start: 285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗